Moreover, our group was the first to demonstrate the therapeutic potential of restoring tumor suppressor function using RNA-based therapeutics in liver cancer, initially demonstrating that p53 restoration sensitizes p53-deficient cancers to mTOR inhibition and subsequently showing that p53 restoration enhances anti-tumor immunity 26. This evidence concerns the gene TP53 and liver cancer.